INBIOMOTION
Inbiomotion is focused on the development and commercialization of a biomarker that predicts metastasis to improve patients' quality of life by personalizing the adjuvant treatment of early stage breast cancer. Founded in 2010 by Dr. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions. Inbiomotion's unique diagnostic assay is based on a highly selective single gene biomarker. Data generated thus far suggests such biomarker can identify early stage breast cancer patien... ts that will benefit from bisphosphonate adjuvant treatment improving their overall and invasive disease free survival. It can further predict at an early stage a patient's risk of metastases relapse from primary tumors. The selectivity of the lead biomarker has the potential to advance the clinical standard of care using personalized medicine.
INBIOMOTION
Social Links:
Industry:
Biotechnology Genetics Health Diagnostics Therapeutics
Founded:
2010-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.inbiomotion.com
Total Employee:
1+
Status:
Active
Contact:
+34932556115
Email Addresses:
[email protected]
Total Funding:
5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Apache Global Site Tag
Current Advisors List
Current Employees Featured
Founder
Investors List
Alta Life Sciences
Alta Life Sciences investment in Venture Round - Inbiomotion
ICF Capital
ICF Capital investment in Venture Round - Inbiomotion
Fundación Vila Casas
Fundación Vila Casas investment in Series B - Inbiomotion
Caixa Capital Risc
Caixa Capital Risc investment in Series B - Inbiomotion
Ysios Capital
Ysios Capital investment in Series B - Inbiomotion
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Inbiomotion
Ysios Capital
Ysios Capital investment in Series A - Inbiomotion
Official Site Inspections
http://www.inbiomotion.com Semrush global rank: 5.93 M Semrush visits lastest month: 1.39 K
- Host name: 213.158.94.180.static.teamblue-ops.net
- IP address: 213.158.94.180
- Location: Italy
- Latitude: 43.1479
- Longitude: 12.1097
- Timezone: Europe/Rome
More informations about "Inbiomotion"
in.bio.motion
Adjuvant bisphosphonates are generally recommended by clinical guidelines for postmenopausal women with early breast cancer deemed at significant risk for recurrence. We have developed …See details»
Inbiomotion - Crunchbase Company Profile & Funding
Inbiomotion is a personalized medicine company developing biomarkers that can predict bone metastasis in cancers.See details»
About us | in.bio.motion
Prof Rob E. Coleman MD, MBBS, FRCP, FRCPE · Chairman Dr. Coleman is Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield, UK. Dr. Coleman has been instrumental in developing …See details»
Inbiomotion - Contacts, Employees, Board Members, Advisors
Inbiomotion is a personalized medicine company developing biomarkers that can predict bone metastasis in cancers.See details»
Inbiomotion Company Profile 2024: Valuation, Funding …
Information on valuation, funding, cap tables, investors, and executives for Inbiomotion. Use the PitchBook Platform to explore the full profile.See details»
Inbiomotion - Funding, Financials, Valuation & Investors
Inbiomotion is a personalized medicine company developing biomarkers that can predict bone metastasis in cancers.See details»
Inbiomotion - Company Profile - Tracxn
3 days ago Inbiomotion - Developer of biomarkers to predict bone metastasis in cancer patients. Raised a total funding of $4.91M over 5 rounds from 6 investors.See details»
In Motion Organization
Our organization was established with the hopes to promote health and wellbeing and create positive learning experiences for young people in our community.See details»
Inbiomotion - VentureRadar
Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2010 with the goal of developing biomarkers that predict bone metastasis to improve the cancer patient’s …See details»
Inbiomotion appoints Ralf van den Berg as Chief Operating Officer
Barcelona, December 20, 2022; Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast …See details»
Source LDPath and Inbiomotion sign an exclusive agreement for …
May 28, 2024 Source LDPath, an industry-leading provider of genomic services and healthcare diagnostics, and Inbiomotion, a company commercializing its proprietary MAF Test® for …See details»
Inbiomotion CEO and Key Executive Team | Craft.co
Inbiomotion's Executive Chairman is Joël Jean-Mairet. Other executives include Roger Gomis, Founder and CSO, Non-Executive Director; Jon Askaa, Non-Executive Director – Independent …See details»
Inbiomotion - Tech Stack, Apps, Patents & Trademarks
Nov 10, 2024 Inbiomotion uses 7 technology products and services including HTML5, Office 365, and Apache Server, according to G2 Stack. Inbiomotion is actively using 9 technologies …See details»
Inbiomotion, a great example of tech transfer by Roger Gomis
The Science Blog “Eduscopi” publishes an interview with ICREA researcher Roger Gomis, leader of the Growth Control and Cancer Metastasis Lab at IRB Barcelona and founder of …See details»
Inbiomotion and Source BioScience exclusive agreement for MAF …
Feb 8, 2024 Together, Inbiomotion and Source BioScience are committed to delivering innovative solutions that revolutionize the landscape of personalised medicine, ultimately …See details»
Inbiomotion - Crunchbase
Inbiomotion is a personalized medicine company developing biomarkers that can predict bone metastasis in cancers.See details»
Perspective for Oncologists | in.bio.motion
Inbiomotion's purpose is to help prevent metastasis in high-risk patients. As a crucial step, we are working towards early-identification of patients with breast cancer who are likely to develop …See details»
MAF Test® by Inbiomotion | Precision Medicine | IHC | Services
The MAF Test® by Inbiomotion is an advanced diagnostic tool designed to enhance treatment decisions in early-stage breast cancer.See details»
Inbiomotion validates its test, which will help reduce mortality in ...
Inbiomotion, a spin-off from IRB Barcelona, developed a unique single-gene-based biomarker for the personalised adjuvant treatment of early-stage breast cancer patients. The study has …See details»